Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Reports Mixed Q2 2025 Earnings, Beats Revenue Estimates and Narrows Loss

Last update: Aug 5, 2025

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company’s revenue and earnings per share (EPS) figures, alongside its reaffirmed full-year guidance, provide insight into its current trajectory and market positioning.

Key Financial Highlights

Revenue Beat: Ultragenyx posted Q2 2025 revenue of $166.5 million, slightly above the consensus estimate of $164.8 million. This represents a modest outperformance of approximately 1%.
Narrower-than-Expected Loss: The company reported an EPS of -$1.17, better than the anticipated -$1.32, reflecting improved cost management or revenue strength.
Product Performance: Crysvita®, the company’s leading therapy, generated $120 million, while Dojolvi® contributed $23 million, both in line with internal expectations.

Market Reaction

Following the earnings release, Ultragenyx shares saw an after-hours gain of ~1.94%, suggesting cautious optimism among investors. Over the past month, the stock has declined ~28.1%, but the recent uptick indicates some relief after the earnings beat. Short-term performance (last week and two weeks) shows minor gains of 0.03% and 0.08%, respectively, suggesting muted sentiment prior to the report.

Full-Year and Q3 Outlook

The company reaffirmed its 2025 revenue guidance of $640 million to $670 million, with Crysvita expected to contribute $460 million to $480 million and Dojolvi projected at $90 million to $100 million.
Analysts currently estimate full-year 2025 sales at $665 million, aligning closely with Ultragenyx’s forecast.
For Q3 2025, Wall Street expects revenue of $167.8 million and an EPS of -$1.32, setting a benchmark for the next earnings report.

Press Release Summary

The earnings update primarily emphasized:

Steady revenue growth driven by Crysvita and Dojolvi.
Reaffirmation of full-year guidance, signaling confidence in meeting targets.
No major pipeline updates or unexpected operational developments.

Conclusion

Ultragenyx’s Q2 results reflect a slight revenue beat and a narrower loss than expected, which appears to have tempered some investor concerns. The reaffirmed guidance suggests stability, though the stock’s longer-term downtrend indicates broader market skepticism.

For a deeper dive into Ultragenyx’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.